FGL1 is confined to the liver and pancreas under normal conditions, and elevated in human cancers such as lung cancer, prostate cancer, melanoma, and colorectal cancer, associated with a poor prognosis and resistance to anti‐PD‐1/B7‐H1 therapy.42, 43. Here, FGL1 is linked to prostate carcinoma.